European task force on atopic dermatitis position paper

treatment of parental atopic dermatitis during preconception, pregnancy and lactation period

C. Vestergaard, A. Wollenberg, S. Barbarot, S. Christen-Zaech, M. Deleuran, P. Spuls, C. Flohr, M. Trzeciak, L. von Kobyletzki, J. Seneschal, C. Paul, T. Bieber, T. Werfel, R. Fölster-Holst, U. Darsow, U. Gieler, Svensson, M. Cork, J. F. Stalder, L. De Raeve & 9 others B. Kunz, D. Simon, P. Chernyshov, D. Hijnen, C. Gelmetti, J. Ring, A. Taieb, M. de Bruin-Weller, J. P. Thyssen

Research output: Contribution to journalArticle

Abstract

Atopic dermatitis (AD) is a common inflammatory skin disease that affects both children and adults, including a large number of adults of reproductive age. Several guidelines for the treatment of AD exist, yet specific recommendations for the treatment of pregnant or lactating women and for adults planning to have a child are often lacking. This position paper from the European Task force on Atopic Dermatitis (ETFAD) is based on up-to-date scientific literature on treating pregnant and lactating women as wells as adults with AD planning to have a child. It is based on the expert opinions of members of the ETFAD and on existing safety data on the proposed treatments, many of which are derived from patients with other inflammatory diseases or from transplantation medicine. For treating future parents, as well as pregnant and lactating women with AD, the use of topical treatments including moisturizers, topical corticosteroids, tacrolimus, antiseptics such as chlorhexidine, octenidine, potassium permanganate and sodium hypochlorite (bleach) is deemed to be safe. Ultraviolet (UV) therapy may also be used. Systemic treatment should be prescribed only after careful consideration. According to the opinion of the ETFAD, treatment should be restricted to systemic corticosteroids and cyclosporine A, and, in selected cases, azathioprine.

Original languageEnglish
Pages (from-to)1644-1659
JournalJournal of the European Academy of Dermatology and Venereology
Volume33
Issue number9
DOIs
Publication statusPublished - Jan 1 2019

Fingerprint

Advisory Committees
Atopic Dermatitis
Lactation
Pregnancy
octenidine
Therapeutics
Pregnant Women
Adrenal Cortex Hormones
Ultraviolet Therapy
Potassium Permanganate
Literature
Sodium Hypochlorite
Local Anti-Infective Agents
Chlorhexidine
Azathioprine
Expert Testimony
Tacrolimus
Skin Diseases
Cyclosporine
Transplantation

ASJC Scopus subject areas

  • Dermatology
  • Infectious Diseases

Cite this

European task force on atopic dermatitis position paper : treatment of parental atopic dermatitis during preconception, pregnancy and lactation period. / Vestergaard, C.; Wollenberg, A.; Barbarot, S.; Christen-Zaech, S.; Deleuran, M.; Spuls, P.; Flohr, C.; Trzeciak, M.; von Kobyletzki, L.; Seneschal, J.; Paul, C.; Bieber, T.; Werfel, T.; Fölster-Holst, R.; Darsow, U.; Gieler, U.; Svensson; Cork, M.; Stalder, J. F.; De Raeve, L.; Kunz, B.; Simon, D.; Chernyshov, P.; Hijnen, D.; Gelmetti, C.; Ring, J.; Taieb, A.; de Bruin-Weller, M.; Thyssen, J. P.

In: Journal of the European Academy of Dermatology and Venereology, Vol. 33, No. 9, 01.01.2019, p. 1644-1659.

Research output: Contribution to journalArticle

Vestergaard, C, Wollenberg, A, Barbarot, S, Christen-Zaech, S, Deleuran, M, Spuls, P, Flohr, C, Trzeciak, M, von Kobyletzki, L, Seneschal, J, Paul, C, Bieber, T, Werfel, T, Fölster-Holst, R, Darsow, U, Gieler, U, Svensson, Cork, M, Stalder, JF, De Raeve, L, Kunz, B, Simon, D, Chernyshov, P, Hijnen, D, Gelmetti, C, Ring, J, Taieb, A, de Bruin-Weller, M & Thyssen, JP 2019, 'European task force on atopic dermatitis position paper: treatment of parental atopic dermatitis during preconception, pregnancy and lactation period', Journal of the European Academy of Dermatology and Venereology, vol. 33, no. 9, pp. 1644-1659. https://doi.org/10.1111/jdv.15709
Vestergaard, C. ; Wollenberg, A. ; Barbarot, S. ; Christen-Zaech, S. ; Deleuran, M. ; Spuls, P. ; Flohr, C. ; Trzeciak, M. ; von Kobyletzki, L. ; Seneschal, J. ; Paul, C. ; Bieber, T. ; Werfel, T. ; Fölster-Holst, R. ; Darsow, U. ; Gieler, U. ; Svensson ; Cork, M. ; Stalder, J. F. ; De Raeve, L. ; Kunz, B. ; Simon, D. ; Chernyshov, P. ; Hijnen, D. ; Gelmetti, C. ; Ring, J. ; Taieb, A. ; de Bruin-Weller, M. ; Thyssen, J. P. / European task force on atopic dermatitis position paper : treatment of parental atopic dermatitis during preconception, pregnancy and lactation period. In: Journal of the European Academy of Dermatology and Venereology. 2019 ; Vol. 33, No. 9. pp. 1644-1659.
@article{c7f2c42a77174c2599a736046fae7a32,
title = "European task force on atopic dermatitis position paper: treatment of parental atopic dermatitis during preconception, pregnancy and lactation period",
abstract = "Atopic dermatitis (AD) is a common inflammatory skin disease that affects both children and adults, including a large number of adults of reproductive age. Several guidelines for the treatment of AD exist, yet specific recommendations for the treatment of pregnant or lactating women and for adults planning to have a child are often lacking. This position paper from the European Task force on Atopic Dermatitis (ETFAD) is based on up-to-date scientific literature on treating pregnant and lactating women as wells as adults with AD planning to have a child. It is based on the expert opinions of members of the ETFAD and on existing safety data on the proposed treatments, many of which are derived from patients with other inflammatory diseases or from transplantation medicine. For treating future parents, as well as pregnant and lactating women with AD, the use of topical treatments including moisturizers, topical corticosteroids, tacrolimus, antiseptics such as chlorhexidine, octenidine, potassium permanganate and sodium hypochlorite (bleach) is deemed to be safe. Ultraviolet (UV) therapy may also be used. Systemic treatment should be prescribed only after careful consideration. According to the opinion of the ETFAD, treatment should be restricted to systemic corticosteroids and cyclosporine A, and, in selected cases, azathioprine.",
author = "C. Vestergaard and A. Wollenberg and S. Barbarot and S. Christen-Zaech and M. Deleuran and P. Spuls and C. Flohr and M. Trzeciak and {von Kobyletzki}, L. and J. Seneschal and C. Paul and T. Bieber and T. Werfel and R. F{\"o}lster-Holst and U. Darsow and U. Gieler and Svensson and M. Cork and Stalder, {J. F.} and {De Raeve}, L. and B. Kunz and D. Simon and P. Chernyshov and D. Hijnen and C. Gelmetti and J. Ring and A. Taieb and {de Bruin-Weller}, M. and Thyssen, {J. P.}",
year = "2019",
month = "1",
day = "1",
doi = "10.1111/jdv.15709",
language = "English",
volume = "33",
pages = "1644--1659",
journal = "Journal of the European Academy of Dermatology and Venereology",
issn = "0926-9959",
publisher = "wiley",
number = "9",

}

TY - JOUR

T1 - European task force on atopic dermatitis position paper

T2 - treatment of parental atopic dermatitis during preconception, pregnancy and lactation period

AU - Vestergaard, C.

AU - Wollenberg, A.

AU - Barbarot, S.

AU - Christen-Zaech, S.

AU - Deleuran, M.

AU - Spuls, P.

AU - Flohr, C.

AU - Trzeciak, M.

AU - von Kobyletzki, L.

AU - Seneschal, J.

AU - Paul, C.

AU - Bieber, T.

AU - Werfel, T.

AU - Fölster-Holst, R.

AU - Darsow, U.

AU - Gieler, U.

AU - Svensson,

AU - Cork, M.

AU - Stalder, J. F.

AU - De Raeve, L.

AU - Kunz, B.

AU - Simon, D.

AU - Chernyshov, P.

AU - Hijnen, D.

AU - Gelmetti, C.

AU - Ring, J.

AU - Taieb, A.

AU - de Bruin-Weller, M.

AU - Thyssen, J. P.

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Atopic dermatitis (AD) is a common inflammatory skin disease that affects both children and adults, including a large number of adults of reproductive age. Several guidelines for the treatment of AD exist, yet specific recommendations for the treatment of pregnant or lactating women and for adults planning to have a child are often lacking. This position paper from the European Task force on Atopic Dermatitis (ETFAD) is based on up-to-date scientific literature on treating pregnant and lactating women as wells as adults with AD planning to have a child. It is based on the expert opinions of members of the ETFAD and on existing safety data on the proposed treatments, many of which are derived from patients with other inflammatory diseases or from transplantation medicine. For treating future parents, as well as pregnant and lactating women with AD, the use of topical treatments including moisturizers, topical corticosteroids, tacrolimus, antiseptics such as chlorhexidine, octenidine, potassium permanganate and sodium hypochlorite (bleach) is deemed to be safe. Ultraviolet (UV) therapy may also be used. Systemic treatment should be prescribed only after careful consideration. According to the opinion of the ETFAD, treatment should be restricted to systemic corticosteroids and cyclosporine A, and, in selected cases, azathioprine.

AB - Atopic dermatitis (AD) is a common inflammatory skin disease that affects both children and adults, including a large number of adults of reproductive age. Several guidelines for the treatment of AD exist, yet specific recommendations for the treatment of pregnant or lactating women and for adults planning to have a child are often lacking. This position paper from the European Task force on Atopic Dermatitis (ETFAD) is based on up-to-date scientific literature on treating pregnant and lactating women as wells as adults with AD planning to have a child. It is based on the expert opinions of members of the ETFAD and on existing safety data on the proposed treatments, many of which are derived from patients with other inflammatory diseases or from transplantation medicine. For treating future parents, as well as pregnant and lactating women with AD, the use of topical treatments including moisturizers, topical corticosteroids, tacrolimus, antiseptics such as chlorhexidine, octenidine, potassium permanganate and sodium hypochlorite (bleach) is deemed to be safe. Ultraviolet (UV) therapy may also be used. Systemic treatment should be prescribed only after careful consideration. According to the opinion of the ETFAD, treatment should be restricted to systemic corticosteroids and cyclosporine A, and, in selected cases, azathioprine.

UR - http://www.scopus.com/inward/record.url?scp=85068145858&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85068145858&partnerID=8YFLogxK

U2 - 10.1111/jdv.15709

DO - 10.1111/jdv.15709

M3 - Article

VL - 33

SP - 1644

EP - 1659

JO - Journal of the European Academy of Dermatology and Venereology

JF - Journal of the European Academy of Dermatology and Venereology

SN - 0926-9959

IS - 9

ER -